Navigation Links
BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
Date:6/29/2010

TEL AVIV, Israel, June 29, 2010 /PRNewswire-FirstCall/ -- BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced today that its Add-On product, the HyperQ AD-100 (http://www.bsp.co.il/pdf/HyperQ AD-100 Pic.pdf), intended for improved diagnostic performance of Stress ECG, has been granted the European CE conformance mark. The HyperQ AD-100 product is an add-on system with the HyperQ technology which is incorporated in parallel to existing standard stress ECG systems. The integration of the HyperQ AD-100 into Stress ECG systems enables accurate and sensitive diagnosis of Ischemic Heart Disease, a leading cause of death in the world.

The unique technology developed by BSP is implemented in a non invasive manner and does not involve exposure to radiation or other hazards to patients. It is highly effective in diagnosing sick people and in ruling out disease in healthy individuals. The HyperQ AD-100 enables physicians to benefit from the clinical advantages of the technology without the need to replace their existing installed Stress ECG system.

BSP CEO, Nissim Greisas: "The integration of the HyperQ Add-On systems into the vast installed base of standard Stress ECG systems significantly expands our potential global market. The worldwide annual stress ECG system market is estimated at $200M, and the total standard ECG installed base represents an estimated $800M market for the new product."

CE mark was also granted to BSP's software product - the HyperQ-AN. This product enables analysis with the unique HyperQ technology and can be employed in OEM and licensing business models in existing commercial stress ECG systems, such as the company's collaboration with Schiller AG.

About BSP

Founded in 2000, BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of cardiovascular disease. BSP's proprietary HyperQ(TM) technology is implemented in cardiac systems that offer accurate, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of ischemic heart disease in broad populations. BSP is a traded company on the Tel Aviv Stock Exchange since 2006 (TASE:BSP). The company's international offices are located in Tel Aviv, Israel and Rockville, Maryland, USA.

    For more information please contact:

    Nissim Greisas, CEO, Biological Signal Processing Ltd.
    nissim@bspmedical.com
    Tel. +972-3-6474840



'/>"/>
SOURCE BSP - Biological Signal Processing Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
2. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
3. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
4. Acuo Technologies Announces Patent Granted for Asset Communication Format Within a Computer Network
5. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
6. SPO Medical Granted Innovative Baby Monitoring Patent
7. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
8. FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
9. Emergency Use Authorization Granted For BioCrysts Peramivir
10. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
11. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. Stock-Callers.com assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: http://stock-callers.com/registration ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):